Alzamend Neuro
$1
50
-$0.02-1.97% Thursday 20:00
Statistics
Day High
1.03
Day Low
0.98
52W High
9.45
52W Low
0.98
Volume
93,397
Avg. Volume
143,065
Mkt Cap
3.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
1JulExpected
Expected EPS
-0.67
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-10.21MNet Income
Analyst Ratings
$28.00Average Price Target
The highest estimate is 28.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ALZN. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Anavex Life Sciences
AVXL
Mkt Cap684.57M
AC Immune SA
ACIU
Mkt Cap340.03M
Prothena
PRTA
Mkt Cap578.67M
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Annovis Bio
ANVS
Mkt Cap48.93M
Athira Pharma Inc
ATHA
Mkt Cap16.39M
About
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Show more...
CEO
Mr. Stephan Jackman
Employees
4
Country
US
ISIN
US02262M6057
Listings
0 Comments
Share your thoughts
FAQ
What is Alzamend Neuro stock price today?▼
The current price of ALZN is $1 USD — it has decreased by -1.97% in the past 24 hours. Watch Alzamend Neuro stock price performance more closely on the chart.
What is Alzamend Neuro stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alzamend Neuro stocks are traded under the ticker ALZN.
Is Alzamend Neuro stock price growing?▼
ALZN stock has fallen by -4.77% compared to the previous week, the month change is a -46.81% fall, over the last year Alzamend Neuro has showed a -1.97% decrease.
What is Alzamend Neuro market cap?▼
Today Alzamend Neuro has the market capitalization of 3.8M
When is the next Alzamend Neuro earnings date?▼
Alzamend Neuro is going to release the next earnings report on July 01, 2026.
What were Alzamend Neuro earnings last quarter?▼
ALZN earnings for the last quarter are -0.58 USD per share, whereas the estimation was -1.45 USD resulting in a +60% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alzamend Neuro revenue for the last year?▼
Alzamend Neuro revenue for the last year amounts to 0 USD.
What is Alzamend Neuro net income for the last year?▼
ALZN net income for the last year is -10.21M USD.
How many employees does Alzamend Neuro have?▼
As of April 03, 2026, the company has 4 employees.
In which sector is Alzamend Neuro located?▼
Alzamend Neuro operates in the Health Care sector.
When did Alzamend Neuro complete a stock split?▼
The last stock split for Alzamend Neuro was on May 12, 2025 with a ratio of 1:9.
Where is Alzamend Neuro headquartered?▼
Alzamend Neuro is headquartered in Atlanta, US.